{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:37:25Z","timestamp":1763534245936,"version":"3.37.3"},"reference-count":42,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2021,10,22]]},"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The risk of developing diffuse large B-cell lymphoma (DLBCL) is increased in many rheumatic diseases (RDs). It is possible that RD-associated DLBCL is a distinct subset within the category of \u2018DLBCL\u2019, exhibiting characteristic biological features and clinical behaviour. However, information on RD-associated DLBCL is limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched the V.A. Nasonova Research Institute of Rheumatology (Russia) database from 1996 to 2021 for patients with RDs and coexisting DLBCL. Prognostic factors including the International Prognostic Index (IPI), bulk disease and<jats:italic>c-MYC\/8q24<\/jats:italic>gene rearrangements were analysed. Furthermore, we stratified DLBCLs as germinal centre B-cell (GCB) subtype and non-GCB subtype based on Hans\u2019 immunohistochemical algorithm and also examined Epstein-Barr virus (EBV) status.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-seven patients with RD-associated DLBCL were identified. Twenty patients had primary Sjogren\u2019s syndrome, three had systemic lupus erythematosus, two had rheumatoid arthritis and two had systemic sclerosis. Secondary Sjogren\u2019s syndrome was found in four patients. The median age at the time of diagnosis of DLBCL was 59 years with a female predominance (26:1). Based on IPI, 16 patients were assigned to the intermediate-high and high-risk groups. Bulk disease was detected in 29% of patients. Of the 20 examined cases, 4 (20%) were classified as the GCB subtype and 16 (80%) were classified as the non-GCB subtype. EBV was detected in 2 of the 21 tested cases (10%), and the<jats:italic>c-MYC\/8q24<\/jats:italic>gene rearrangement was not found in any of the 19 examined cases. After the lymphoma diagnosis, the median overall survival (OS) was 10 months (range: 0\u2013238 months).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Except for the more common non-GCB subtype, we did not identify any other prognostic factor that could influence the prognosis of patients with RD-associated DLBCL. We believe that short OS in our patients was predominantly associated with decreased tolerance to lymphoma treatment.<\/jats:p><\/jats:sec>","DOI":"10.1136\/lupus-2021-000561","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T16:47:34Z","timestamp":1637081254000},"page":"e000561","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Analysis of prognostic factors in diffuse large B-cell lymphoma associated with rheumatic diseases"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8428-1281","authenticated-orcid":false,"given":"Vadim","family":"Gorodetskiy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalya","family":"Probatova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Obukhova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Vasilyev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,11,16]]},"reference":[{"key":"2024052109583074000_8.1.e000561.1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2271-1"},{"key":"2024052109583074000_8.1.e000561.2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj004"},{"key":"2024052109583074000_8.1.e000561.3","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24287"},{"key":"2024052109583074000_8.1.e000561.4","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/j.clml.2017.11.009","article-title":"Characterizing autoimmune disease-associated diffuse large B-cell lymphoma in a SEER-Medicare cohort","volume":"18","author":"Koff","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2024052109583074000_8.1.e000561.5","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.3390\/jcm9123794","article-title":"Pathogenetic Mechanisms Implicated in Sj\u00f6gren\u2019s Syndrome Lymphomagenesis: A Review of the Literature","volume":"9","author":"Stergiou","year":"2020","journal-title":"J Clin Med"},{"key":"2024052109583074000_8.1.e000561.6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1545"},{"key":"2024052109583074000_8.1.e000561.7","unstructured":"Swerdlow SH , Campo E , Harris NL , et al , eds. WHO classification of tumours of hematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: IARC, 2017."},{"key":"2024052109583074000_8.1.e000561.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"2024052109583074000_8.1.e000561.9","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0105-4","article-title":"History of autoimmune conditions and lymphoma prognosis","volume":"8","author":"Kleinstern","year":"2018","journal-title":"Blood Cancer J"},{"key":"2024052109583074000_8.1.e000561.10","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwu290"},{"key":"2024052109583074000_8.1.e000561.11","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.2019002729","article-title":"International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI","volume":"135","author":"Ruppert","year":"2020","journal-title":"Blood"},{"key":"2024052109583074000_8.1.e000561.12","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/hon.2525","article-title":"Rheumatoid arthritis and lymphoma: incidence, pathogenesis, biology, and outcome","volume":"36","author":"Klein","year":"2018","journal-title":"Hematol Oncol"},{"key":"2024052109583074000_8.1.e000561.13","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14136"},{"key":"2024052109583074000_8.1.e000561.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.137"},{"key":"2024052109583074000_8.1.e000561.15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276246"},{"key":"2024052109583074000_8.1.e000561.16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-038257"},{"key":"2024052109583074000_8.1.e000561.17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-345256"},{"key":"2024052109583074000_8.1.e000561.18","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2009.065227"},{"key":"2024052109583074000_8.1.e000561.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3947"},{"key":"2024052109583074000_8.1.e000561.20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-647602"},{"key":"2024052109583074000_8.1.e000561.21","first-page":"315","article-title":"The role of EBV in the pathogenesis of diffuse large B cell lymphoma","volume":"390","author":"Healy","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"key":"2024052109583074000_8.1.e000561.22","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.3390\/cancers13112717","article-title":"Advances in the pathogenesis of EBV-associated diffuse large B cell lymphoma","volume":"13","author":"Chabay","year":"2021","journal-title":"Cancers"},{"key":"2024052109583074000_8.1.e000561.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.22277"},{"key":"2024052109583074000_8.1.e000561.24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/03009742.2019.1696403","article-title":"Population-Based study of patients with primary Sj\u00f6gren's syndrome and lymphoma: lymphoma subtypes, clinical characteristics, and gender differences","volume":"49","author":"Vasaitis","year":"2020","journal-title":"Scand J Rheumatol"},{"key":"2024052109583074000_8.1.e000561.25","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.067108"},{"key":"2024052109583074000_8.1.e000561.26","doi-asserted-by":"publisher","DOI":"10.1177\/106689690601400108"},{"key":"2024052109583074000_8.1.e000561.27","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.49.89"},{"key":"2024052109583074000_8.1.e000561.28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199398","article-title":"Clinical characteristics and prognostic significance of EBER positivity in diffuse large B-cell lymphoma: a meta-analysis","volume":"13","author":"Gao","year":"2018","journal-title":"PLoS One"},{"key":"2024052109583074000_8.1.e000561.29","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800396"},{"key":"2024052109583074000_8.1.e000561.30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276766"},{"key":"2024052109583074000_8.1.e000561.31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1482"},{"key":"2024052109583074000_8.1.e000561.32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.9277"},{"key":"2024052109583074000_8.1.e000561.33","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3960\/jslrt.17029","article-title":"Clinicopathological analysis of 320 cases of diffuse large B-cell lymphoma using the Hans classifier","volume":"57","author":"Ichiki","year":"2017","journal-title":"J Clin Exp Hematop"},{"key":"2024052109583074000_8.1.e000561.34","doi-asserted-by":"publisher","DOI":"10.1111\/his.12223"},{"key":"2024052109583074000_8.1.e000561.35","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2019-000324"},{"key":"2024052109583074000_8.1.e000561.36","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","article-title":"Diffuse large B-cell lymphoma","volume":"50","author":"Li","year":"2018","journal-title":"Pathology"},{"key":"2024052109583074000_8.1.e000561.37","first-page":"3602","article-title":"Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone","volume":"15","author":"Horvat","year":"2018","journal-title":"Oncol Lett"},{"key":"2024052109583074000_8.1.e000561.38","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/hon.2498","article-title":"Presence of autoimmune disease affects not only risk but also survival in patients with B-cell non-Hodgkin lymphoma","volume":"36","author":"Kleinstern","year":"2018","journal-title":"Hematol Oncol"},{"key":"2024052109583074000_8.1.e000561.39","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1080\/0284186X.2019.1619936","article-title":"Autoimmune disease in patients with diffuse large B-cell lymphoma: occurrence and impact on outcome","volume":"58","author":"M\u00f6rth","year":"2019","journal-title":"Acta Oncol"},{"key":"2024052109583074000_8.1.e000561.40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/1756-185X.13231","article-title":"Clinical features and outcome of lymphoma patients with pre-existing autoimmune diseases","volume":"21","author":"Shih","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"2024052109583074000_8.1.e000561.41","doi-asserted-by":"publisher","DOI":"10.1002\/art.11144"},{"key":"2024052109583074000_8.1.e000561.42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.6227"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2021-000561","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T16:58:46Z","timestamp":1716310726000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2021-000561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,11,16]]},"published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1136\/lupus-2021-000561"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2021-000561","relation":{},"ISSN":["2053-8790"],"issn-type":[{"type":"electronic","value":"2053-8790"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}